Dermatology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Dermatology Drugs Market
The global dermatology drugs market size was valued at USD 38.48 billion in 2022 and is projected to grow from USD 40.55 billion in 2023 to USD 70.59 billion by 2030, exhibiting a CAGR of 8.2% during the forecast period of 2023-2030.
The pandemic slowed down the Derma Drugs Market at the beginning as patient consultations were reduced and supply chains hampered, which caused a downfall in scripts. However, the upward push of telemedicine exacerbated the demand for dermatological treatment which has thwarted the dermatology drugs market growth.
The Dermatology Drugs Market is pushed by using the growing occurrence of pores and skin problems like acne and psoriasis, accelerated recognition of skin fitness, and improvements in revolutionary therapies. Additionally, an aging populace and way of life adjustments contributing to skin problems further boost demand for dermatological products.
Personalized remedy is a developing fashion in dermatology, focusing on tailoring treatments to character sufferers based on their specific characteristics. Genetic checking out is used to identify sufferers with unique genetic predispositions to pores and skin sicknesses, allowing extra-centered and effective remedies and expanding the dermatology drugs market share globally. Precision medication tactics also refine this by considering a patient's everyday genetic makeup and disorder characteristics to broaden customized treatment plans. This personalized approach aims to enhance treatment outcomes and decrease unfavorable consequences.
Comprehensive Analysis of Dermatology Drugs Market
The Dermatology Drugs Market is segmented by software, path of administration, and distribution channel. The psoriasis section is led by growing incidence and cognizance, while the pimples phase is also predicted to develop appreciably. In phrases of administration, the parenteral phase dominates, pushed using biological launches and favorable compensation, with the topical phase projected to create as well. Hospital pharmacies preserve the most significant market proportion because of extended patient visits, even as online pharmacies are anticipated to extend rapidly due to the upward thrust of e-trade.
The North America region led the dermatology drugs market by benefitting a size of USD 18.98 billion in 2022 due to the growing affected person population, a surge in product launches, and developing projects by using authorities groups to help the research and development.
The leading players in the dermatology drugs market significantly impact its growth trajectory and establish industry standards. Key players such as AbbVie, Inc. (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Eli Lilly and Company (U.S.), GALDERMA (Switzerland), GSK plc (U.K.), Almirall, S.A. (Spain), and Bausch Health Companies Inc. (Canada) contribute to a competitive landscape that drives innovation and market advancement.
In June 2023, Eli Lilly and Company has discovered a deal to buy DICE Therapeutics, Inc. To decorate its immunology pipeline.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 8.2% from 2023-2030
Unit Value (USD Billion)
Segmentation By Application
Acne
Atopic Dermatitis
Psoriasis
Others
By Route of Administration
Oral
Parenteral
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America (By Application, Route of Administration, Distribution Channel, and Country)
U.S. (By Application)
Canada (By Application)
Europe (By Application, Route of Administration, Distribution Channel, and Country/Sub-Region)
U.K. (By Application)
Germany (By Application)
France (By Application)
Italy (By Application)
Spain (By Application)
Scandinavia (By Application)
Rest of Europe (By Application)
Asia Pacific (By Application, Route of Administration, Distribution Channel, and Country/Sub-Region)
China (By Application)
Japan (By Application)
India (By Application)
Australia (By Application)
Southeast Asia (By Application)
Rest of Asia Pacific (By Application)
Latin America (By Application, Route of Administration, Distribution Channel, and Country/Sub-Region)
Brazil (By Application)
Mexico (By Application)
Rest of Latin America (By Application)
Middle East & Africa (By Application, Route of Administration, Distribution Channel, and Country/Sub-Region)
GCC (By Application)
South Africa (By Application)
Rest of the Middle East & Africa (By Application)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Key Dermatologic Conditions, By Key Countries, 2022
- 4.2. New Product Launches, By Key Players
- 4.3. Pipeline Analysis
- 4.4. Key Industry Developments: Mergers, Acquisitions and Partnerships
- 4.5. Impact of COVID-19 on the Market
- 5. Global Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Application
- 5.1.1. Acne
- 5.1.2. Atopic Dermatitis
- 5.1.3. Psoriasis
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast – By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.2.3. Topical
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies
- 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Application
- 6.1.1. Acne
- 6.1.2. Atopic Dermatitis
- 6.1.3. Psoriasis
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast – By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.2.3. Topical
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies
- 6.3.3. Online Pharmacies
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Application
- 6.4.2. Canada
- 6.4.2.1. By Application
- 7. Europe Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Application
- 7.1.1. Acne
- 7.1.2. Atopic Dermatitis
- 7.1.3. Psoriasis
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast – By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.2.3. Topical
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Application
- 7.4.2. Germany
- 7.4.2.1. By Application
- 7.4.3. France
- 7.4.3.1. By Application
- 7.4.4. Italy
- 7.4.4.1. By Application
- 7.4.5. Spain
- 7.4.5.1. By Application
- 7.4.6. Scandinavia
- 7.4.6.1. By Application
- 7.4.7. Rest of Europe
- 7.4.7.1. By Application
- 8. Asia Pacific Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Application
- 8.1.1. Acne
- 8.1.2. Atopic Dermatitis
- 8.1.3. Psoriasis
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast – By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.2.3. Topical
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.4.1. China
- 8.4.1.1. By Application
- 8.4.2. Japan
- 8.4.2.1. By Application
- 8.4.3. India
- 8.4.3.1. By Application
- 8.4.4. Australia
- 8.4.4.1. By Application
- 8.4.5. Southeast Asia
- 8.4.5.1. By Application
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Application
- 9. Latin America Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Application
- 9.1.1. Acne
- 9.1.2. Atopic Dermatitis
- 9.1.3. Psoriasis
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast – By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.2.3. Topical
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
- 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Application
- 9.4.2. Mexico
- 9.4.2.1. By Application
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Application
- 10. Middle East & Africa Dermatology Drugs Market Analysis, Insights and Forecast, 2019-2030
- 10.1. Market Analysis, Insights and Forecast – By Application
- 10.1.1. Acne
- 10.1.2. Atopic Dermatitis
- 10.1.3. Psoriasis
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast – By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.2.3. Topical
- 10.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Application
- 10.4.2. South Africa
- 10.4.2.1. By Application
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Application
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2022)
- 11.2. Profiles of Players Operating in the Market
- 11.2.1. AbbVie, Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (based on availability)
- 11.2.2. Novartis AG
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (based on availability)
- 11.2.3. Pfizer, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (based on availability)
- 11.2.4. Johnson & Johnson Services, Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (based on availability)
- 11.2.5. Eli Lilly and Company
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (based on availability)
- 11.2.6. GALDERMA
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (based on availability)
- 11.2.7. GSK plc
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (based on availability)
- 11.2.8. Almirall, S.A
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (based on availability)
- 11.2.9. Bausch Health Companies Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook